So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific research and seems determined to scrap the research grants of Ivy League ...

Pascal Soriot, who runs drugs giant AstraZeneca, has slipped to third place in our annual survey, after being replaced by the ...

It plans to invest $50 billion in the US over five years, including building its largest-ever manufacturing facility in ...

NHS England has poured investment into hospitals while neglecting other parts of the service, Lord Ara Darzi concluded last year in his report on a “broken system”. The share of the UK health budget ...

We will be totally self-sufficient for the supply of medicines to American patients.” AstraZeneca CEO Pascal Soriot on the ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

President Donald Trump has given major pharmaceutical companies 60 days to slash prescription drug prices or face action.

One of Trump's demands was that the CEOs' companies limit drug costs for states' Medicaid plans to "most-favored nation" ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

New data highlights an unprecedented crisis in National Health Service patient waiting lists and sheds light on how the ...

Just days after telling AstraZeneca how proud he was at its $50 billion investment strategy for the US, President Donald ...